Logo

American Heart Association

  12
  0


Final ID: MDP1042

Disparities in Achieving LDL-C Goals After Revascularization in a Diverse Real-World Cohort

Abstract Body (Do not enter title and authors here): Background
Guidelines and large clinical trials support the cardiovascular benefits of low-density lipoprotein cholesterol (LDL-C) testing and treatment with lipid-lowering therapies (LLT).
Research Questions
What characteristics influence attainment of guideline recommended LDL-C goals in patients undergoing coronary (CAD) or peripheral arterial (PAD) revascularization?
Goals
We analyzed the rates of LDL-C testing within 6 months and LDL-C goal attainment (<70 mg/dL) in a cohort of patients undergoing CAD or PAD revascularization.
Methods
We retrospectively analyzed 8,172 patients from a large health network who underwent percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or peripheral artery revascularization from 2018-2023. Patients without follow-up LDL-C testing >30 days after revascularization were excluded. The associations between clinical variables and LDL-C goal attainment were assessed with logistic regression analysis.
Results
Only about half of the patients (4,319) had LDL-C tests >30 days after their revascularization and were included in the analysis. The median age was 68 years, 2,729 (63%) were male, 1,848 (43%) were Hispanic, 928 (21%) were non-Hispanic Black and 663 (15%) were non-Hispanic White. Overall, 3,373 (78%) patients underwent PCI, 857 (20%) CABG, and 89 (2%) PAD revascularization. Median time to follow-up testing was 11 months (Panel A). Those with earlier follow-up testing, <6 months (35%), had higher utilization of high-intensity statins, ezetimibe, and PCSK9 inhibitors. A follow-up LDL-C <70 mg/dL was achieved in 2,259 (52%) patients with 1,294 (30%) having LDL-C <55 mg/dL (Panel B). Female sex, non-Hispanic Black race/ethnicity, presence of obesity and longer time to LDL-C testing were independently associated with a lower likelihood of achieving LDL-C <70 mg/dL after multivariable adjustment (Panel C).
Conclusions
LDL-C testing and guideline recommended goal attainment were low and female, non-Hispanic Black patients and those with obesity were less likely to reach optimal LDL-C values. Future preventive efforts must focus on efficiently standardizing and implementing an approach to LDL-C testing and lowering after revascularization.
  • Greenberg, Garred  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Lipsitz, Evan  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Forest, Stephen  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Scotti, Andrea  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Latib, Azeem  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Garcia, Mario  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Rodriguez, Carlos  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Gulati, Martha  ( Cedars-Sinai Medical Center , Los Angeles , California , United States )
  • Slipczuk, Leandro  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Lorenzatti, Daniel  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Filtz, Annalisa  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Jaspan, Vita  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Park, Christine  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Kalich, Bethany  ( Amgen Inc , Thousand Oaks , California , United States )
  • Kathe, Niranjan  ( Amgen Inc , Thousand Oaks , California , United States )
  • Dipalo, Katherine  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Browne, Constance  ( Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , United States )
  • Author Disclosures:
    Garred Greenberg: DO NOT have relevant financial relationships | Evan Lipsitz: No Answer | Stephen Forest: DO NOT have relevant financial relationships | Andrea Scotti: No Answer | Azeem Latib: DO have relevant financial relationships ; Consultant:Edwards Lifesciences:Active (exists now) ; Advisor:Supira:Active (exists now) ; Advisor:Shifamed:Active (exists now) ; Advisor:Boston Scientific:Active (exists now) ; Advisor:Medtronic:Active (exists now) ; Advisor:Abbott Vascular:Active (exists now) | Mario Garcia: DO have relevant financial relationships ; Royalties/Patent Beneficiary:Elsevier:Active (exists now) ; Individual Stocks/Stock Options:Pfizer:Active (exists now) ; Royalties/Patent Beneficiary:Wolters-Kluwer:Active (exists now) | Carlos Rodriguez: DO NOT have relevant financial relationships | Martha Gulati: DO NOT have relevant financial relationships | Leandro Slipczuk: DO have relevant financial relationships ; Research Funding (PI or named investigator):Philips:Active (exists now) ; Research Funding (PI or named investigator):Amgen:Active (exists now) | Daniel Lorenzatti: DO NOT have relevant financial relationships | Annalisa Filtz: DO NOT have relevant financial relationships | Vita Jaspan: DO NOT have relevant financial relationships | Christine Park: DO NOT have relevant financial relationships | Bethany Kalich: No Answer | Niranjan Kathe: DO have relevant financial relationships ; Employee:Amgen Inc:Active (exists now) ; Individual Stocks/Stock Options:Amgen Inc:Active (exists now) | Katherine DiPalo: DO NOT have relevant financial relationships | Constance Browne: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Breaking Barriers: Addressing Disparities in Cardiovascular Health and Training

Sunday, 11/17/2024 , 03:15PM - 04:30PM

Moderated Digital Poster Session

More abstracts on this topic:
12,13-diHOME Attenuates Pro-Arrhythmic Effect of High-Fat Diet

Buck Benjamin, Baer Lisa, Deschenes Isabelle, Chinthalapudi Krishna, Gallego-perez Daniel, Stanford Kristin, Hund Thomas, Areiza Natalia, Xu Xianyao, Elliott Austin, Wan Xiaoping, Nassal Drew, Lane Cemantha, Nirengi Shinsuke, James Natasha Maria

ALPACAR Phase 2 Trial of Zerlasiran: Multiple doses of a Small-Interfering RNA Targeting Lipoprotein(a) with 60 weeks Folow Up.

Nissen Steven, Dorresteijn Jannick, Fok Henry, Rider David, Romano Steve, Wolski Kathy, Rambaran Curtis, Wang Qiuqing, Nicholls Stephen, Navar Ann Marie, Ray Kausik, Schwartz Gregory, Szarek Michael, Stroes Erik, Troquay Roland

More abstracts from these authors:
No Second Breakfast: GLP-1 agonists for HFpEF, obesity and AF

Gulati Martha, Sanders Prashanthan

Panel Participant

Gulati Martha

You have to be authorized to contact abstract author. Please, Login
Not Available